Trial Results Indicate Potential for Celecoxib in the Acute Treatment of Migraine Pain
An oral solution of celecoxib, a selective inhibitor of cyclo-oxygenase 2, is superior to placebo for the acute treatment of migraine pain.
An oral solution of celecoxib, a selective inhibitor of cyclo-oxygenase 2, is superior to placebo for the acute treatment of migraine pain.
Researchers found evidence for a divergent association between lifetime MDD and the prevalence and severity of symptoms in patients with migraine.
Individuals with non-migraine headache have a higher risk for tinnitus, sensorineural hearing impairment, and sudden deafness than individuals without chronic headache.
Fremanezumab was found to be effective and well-tolerated in patients with migraine who have failed to respond to prior preventive treatment.
Ubrogepant — a small-molecule, orally delivered, and specific calcitonin gene-related peptide receptor antagonist under investigation for acute treatment of migraine — features a favorable tolerability profile in healthy adults, study results published in Cephalalgia suggest. Calcitonin gene-related peptide receptor antagonism was previously shown to be effective in the acute treatment of migraine attacks. However, the…
Researchers aimed to identify the ocular symptoms driving the reduction in visual quality of life in patients with migraine.
Biofeedback may effectively improve headache and urinary incontinence related to prostatectomy.
Researchers analyzed the efficacy of interdisciplinary multimodal integrated care in patients with chronic migraine and/or tension-type headache.
Researchers examined the association between migraine during pregnancy and the risk for adverse outcomes in the mother and children in a cohort study conducted in Denmark over a period of 8 years.
An association between migraine and metabolic syndrome was observed only in women with a past history of migraine.